Baker McKenzie has advised Keensight Capital (Keensight), one of the leading private equity managers dedicated to pan-European Growth Buyout investments, on the financing aspects of its acquisition of a majority stake in Bedfont® Scientific Ltd. (Bedfont), which designs and manufactures non-invasive breath analysis medical devices.
With a strong track record in both MedTech and the respiratory field, Keensight brings the expertise and network to support Bedfont’s next stage of growth, strengthening its position as a global leader in breath analysis field. By leveraging its international footprint and the resources of the Performance team, Keensight will work hand-in-hand with management to accelerate growth and international expansion, both organically and through acquisitions, while further scaling innovation.
The Baker McKenzie team was led by Banking & Finance Partner, Nick O’Grady with support from Senior Associate, Lana Ahern, Associates, Natalie Lawman and Sarah Hyland, and Trainee Ed Walters.
Commenting on the deal, Nick O’Grady, said: “We’re pleased to have supported the Keensight team on the financing aspects of this strategic acquisition. The transaction marks an exciting step forward for Keensight, reinforcing its growth ambitions and sector leadership.”
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.